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RuSH—Strategies from the Field: Data Collection

Overview
In 2010, the Registry and Surveillance System for
Hemoglobinopathies (RuSH) pilot project was implemented by
the Centers for Disease Control and Prevention (CDC) to collect
state-specific, population-based data on people with sickle
cell disease (SCD) and thalassemia. The 2-year pilot project was
supported and conducted in collaboration with the National
Institutes of Health’s National Heart, Lung, and Blood Institute
(NHLBI).

It is anticipated that these state-based surveillance data will:

Overall project goals included determining the number of
people with SCD and thalassemia and increasing knowledge
and awareness about health care use and outcomes. Seven
states were funded to participate in data collection: California,
Florida, Georgia, Michigan, New York, North Carolina, and
Pennsylvania. Due to the unique nature of the available data
sources in each state, a variety of data collection methods were
employed.

yy Provide information about complications and death rates.
yy Provide information to assist with planning public health

yy Provide estimates of the number of new cases (incidence) of
SCD and thalassemia each year.

yy Provide estimates of the total number of existing cases
(prevalence) of SCD and thalassemia.

yy Provide information on trends in medical care for people
with these disorders.

interventions (i.e., services, health promotion campaigns,
health education, and training) to improve the health of
these populations.

4

RuSH—Strategies from the Field: Data Collection

Strategy Field Reports
The purpose of this document is to showcase the unique ways
in which the states implemented activities designed to meet
the programmatic goals of RuSH. In the following sections, each
state highlights a particular aspect of its data collection process,
including information about the resources needed to operate
or replicate the activity and lessons learned. The intent is to

give a brief overview of the complexity of this project and to
provide contact and programmatic information to other entities
for the potential modification or replication, or both, of activities.
The information in this report was provided by programmatic
team members who worked with CDC staff in spring 2012.

Case Definition
An important initial step in developing the RuSH pilot project
was defining the patients with hemoglobinopathies that
were included in the surveillance efforts. Because most of the
collected information came from preexisting data sources,
and these data sources varied greatly among the seven states,
a case definition was created to help standardize the studied
population as much as possible. A workgroup consisting
of clinicians and public health professionals was established
to help CDC and the NHLBI in creating the definition. Please
note that this definition and its corresponding complications,
procedures, and treatments will be referred to throughout
this document.

LEVEL 1: HIGH
yy Results of a state newborn screening program with
confirmatory testing, or

yy Clinical diagnosis by a physician with documented

confirmatory laboratory testing after the newborn period.

LEVEL 2: PROBABLE
yy Results of a state newborn screening program without
confirmatory testing, or

yy Hemoglobinopathy-related International Classification of

Disease (ICD) -9 or -10 code (see following codes; excluding
sickle cell trait) used during two or more separate health
care encounters, plus one or more hemoglobinopathyassociated complication, treatment, or procedure (see
following lists)

LEVEL 3: POSSIBLE
yy Sickle cell trait ICD -9 or ICD-10 code (see following
codes) used during two or more separate health care
encounters, plus one or more hemoglobinopathy-associated
complication, treatment, or procedure (see following lists ),
or

yy Single health care encounter with a hemoglobinopathy-

related ICD -9 or ICD-10 code(see following codes; excluding
sickle cell trait)

*Health care encounter: Inpatient or outpatient hospitalization or health care visit, including emergency department visits.
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Hemoglobinopathy-Related
International Classification of
Disease (ICD) Codes

Hemoglobinopathy-Associated
Complications

ICD-9

Codes

2. Pneumonia, acute chest syndrome

282.4

Thalassemias

1. Chronic renal failure/Proteinuria
3. Pulmonary hypertension

282.41 Sickle cell thalassemia without crisis

4. Stroke (ischemic or hemorrhagic), transient ischemic attack,
seizures

282.42 Sickle cell thalassemia with crisis

5. Intracranial bleeding

282.49 Other thalassemia

6. Priapism

282.6

Sickle cell disease

282.5

Sickle cell trait

7. Iron overload
8. Gallstones/cholelithiasis, cholecystitis
9. Avascular necrosis

282.60 Sickle cell disease, unspecified

10. Retinal disease

282.61 Hb-SS disease without crisis

11. Splenomegaly, splenic sequestration, hypersplenism
12. Leg ulcers

282.62 Hb-SS disease with crisis

13. Dactylitis

282.63 Sickle cell/Hb-C disease without crisis

14. Osteomyelitis

282.64 Sickle cell/HB-C disease with crisis

Hemoglobinopathy-Associated
Treatments

282.68 Other sickle cell disease without crisis
282.69 Other sickle cell disease with crisis

1. Hydroxyurea

ICD-10 Codes

2. Parenteral analgesics

D56

Thalassemia

3. Iron Chelators

D56.0

Alpha thalassemia

4. Erythropoietin

D56.1

Beta thalassemia

D56.2

Delta-beta thalassemia

D56.8

Other thalassemias

Hemoglobinopathy-Associated
Procedures

D56.9

Thalassemia, unspecified

1. Red cell transfusion

D57

Sickle cell disorders

D57.0

Sickle cell anemia with crisis

D57.1

Sickle cell anemia without crisis

D57.2

Double heterozygous sickling disorders

D57.3

Sickle cell trait

D57.8

Other sickle cell disorders

5. Folic acid

2. Red cell exchange
3. Splenectomy
4. Cholecystectomy
5. Transcranial Doppler

7

RuSH—Strategies from the Field: Data Collection

North Carolina:
Matching Existing Government and Clinical Datasets
Program Overview

6. North Carolina Women’s and Children’s Section Web-based
System (WCSWeb)—NCSCSP client data

The goal of the North Carolina (NC) RuSH project was to
identify the number of people with sickle cell disease (SCD)
or thalassemia who received care and services in North
Carolina during the years 2004–2008. A secondary goal was
to determine what health services this population received
during the same timeframe. Specifically, the NC RuSH project
was designed to collect information from specific datasets from
various governmental and clinical data sources. The existing
datasets included information on demographics, clinical
diagnoses (i.e., laboratory test or International Classification
of Disease, 9th Revision or 10th Revision), mortality, health
care use, medical complications, procedures, and treatment
modalities.

7. North Carolina State Center for Health Statistics—hospital
discharge, Medicaid, and birth and death records
8. North Carolina Disease Event Tracking and Epidemiologic
Collection Tool (NC DETECT)—emergency department data
9. North Carolina Purchase of Medical Care Program
(POMC)—state program insurance claims data
10. North Carolina Immunization Registry (NCIR)—vaccination
data
11. North Carolina State Laboratory of Public Health (SLPH—
newborn and nonnewborn data
12. North Carolina Comprehensive Medical Centers—six
comprehensive sickle cell centers’ client data

This surveillance effort supports North Carolina’s commitment
to ensure that people living with SCD or thalassemia lead an
independent, healthy life. Moreover, the gathered surveillance
data will guide the health practices for program partners
and health care professionals, to better serve populations
affected by hemoglobinopathies. Ultimately, this will increase
the knowledge and awareness of SCD and thalassemia for
stakeholders, policy makers, and residents of North Carolina.
In addition, it will ensure the best use of allocated resources
for the North Carolina Division of Public Health’s Sickle Cell
Syndrome Program (NCSCSP) and better streamline educational
and outreach strategies.

13. University of North Carolina at Greensboro—data analysis
and evaluation
Other resources included staff with specific skill sets, such
as information technology (IT), programmers/coders, data
managers, program coordinators, and epidemiologists. Time
required for data coordination was substantial, as 75%–100%
of the time of one FTE was needed. There also needed to
be consideration for the availability of appropriate computer
software and hardware such as SAS, SPSS, and Microsoft® Excel
2010 to extract, deduplicate, and link data. Budget cost can be
significant if the skill sets and other technology are not readily
available. It is advisable to use in-kind services when possible to
offset cost. These resources were essential for matching existing
datasets within surveillance systems.

Resources Needed:
To successfully conduct statewide surveillance of people
with SCD or thalassemia, it was critical to determine the
systems within state government that provided access to
information on the targeted populations and attain legal
access to these systems. In particular, letters of agreement
or memorandums of agreement, or both, were established
with various governmental agencies, clinical partners, and
community entities to capture patient data. Following is a list
of agencies with which agreements were established to
facilitate the project:

Lessons Learned:
Goals and objectives need to be clearly defined at the onset of
the project; changes in these can affect the project and cause
delays, as well as increase cost and resources. There must be
adequate time allowed so that all partners are able to agree on
deliverables and clearly define the expectations for the work. If
competing agendas and issues of data privacy arise, these may
challenge the prioritization of surveillance activities. There is a
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Sustainability/Translation:

chance that substandard data may be delivered, so this
will require additional review and analysis. Validation of
the quality of the data is necessary. Finally, if only limited
information is available from the datasets requested from
participating partners, this may inhibit the matching of
data among data sources.

The NCSCSP is committed to advancements in the treatment,
research, legislation, and quality of care for people with SCD
or thalassemia, which ultimately might lead to a cure for these
diseases. The RuSH project laid a foundation and framework
to provide a global platform to address hemoglobinopathies
at a level that examines the diseases beyond diagnosis and
treatment. The NC RuSH effort will continue to advocate
and seek resources and opportunities to build a registry for
hemoglobinopathies. Efforts that will continue beyond RuSH
funding include sharing of interagency data, enhancement of
SLPH with the WCSWeb and building of statewide partnerships.

Outcome:
Preliminary findings identified approximately 8,955 unique
individuals with sickle cell disease or thalassemia who were
living in North Carolina during the years of 2004–2008.
Roughly 50% were Level 1 cases, 14% were Level 2 cases, and
36% were Level 3 cases. Analysis of these data allowed public
health officials to derive prevalence and incidence estimates of
hemoglobinopathies in North Carolina, as well as the effects of
these diseases.

The surveillance for hemoglobinopathies provides a model
to investigate the trends and epidemiology of other health
conditions as well, such as heart disease, stroke, or Alzheimer
disease. The NC RuSH project could serve as a model for
all areas of health care to ensure that work being done is
adequate to address the needs of the community affected by
hemoglobinopathies and is based on sound data and practices.
This work is translatable to other areas of public health because
it sets a standard and is an impetus for surveillance. Surveillance
for hemoglobinopathies should be a basic public health activity
to ensure that the appropriate protocols, treatments, and
prevention efforts are being provided at the federal, state, and
local levels.

Data collection for this activity provided opportunities
in the enhancement and evaluation of the NCSCSP. It
benefitted patients, health care providers, community-based
organizations, faith-based communities, policy makers, and the
general public. This type of information helped to determine
quality of care standards, service delivery, and resource
distribution. In addition, it created a road map and model for
accessing data and building interagency collaboration within
state government. The final analysis of the data provided
information and best practices to:

Contact Information
Yvonne Greene
Yvonne.Greene@dhhs.nc.gov
919-707-5717
www.ncsicklecellprogram.org

1. Outline a clear plan and approach for improved medical
treatment, services, and resources.
2. Make a case for continued support of the program.
3. Direct efforts to targeted populations with the greatest need.
4. Shape the development of health promotion messages
and outreach strategies.
5. Increase knowledge of general public.
6. Track trends of the effects of these conditions on
individuals throughout their lifespan.
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Georgia:
Limitations of International Classification of
Disease (ICD) Codes for Defining and Identifying
Hemoglobinopathy Cases
Program Overview

to acquire identified, person-level data from these partners. In
return, partners were assured that the data would be secured
and the process would adhere to all Health Insurance Portability
and Accountability Act protections. Georgia also had a benefit
in this effort, as both sickle cell disease (SCD) and thalassemia
are reportable conditions for children up to 18 years of age
through surveillance for birth defects. Mining, coding, and
deduplicating each of the datasets required the expertise of
at least a part-time data analyst comfortable working with
large administrative datasets. In addition to the data analyst,
the principal investigator and Public Health representative also
devoted significant personnel time to securing necessary datasharing agreements.

Each of the RuSH states used International Classification
of Disease (ICD) codes to identify people with
hemoglobinopathies in at least one administrative dataset.
States also used the ICD ninth or tenth revision (ICD-9 or ICD10) codes to classify mortality data from death certificates and
the International Classification of Diseases, Clinical Modification
(ICD-9-CM or ICD-10-CM) codes to classify morbidity data
from inpatient and outpatient records, public and private
health insurance claims, and public health programs.
While several subcategories of ICD codes were available to
distinguish between different types of hemoglobinopathies,
the coding for clinically relevant types of hemoglobinopathies
in administrative datasets might not always be specific.
Therefore, ICD codes for common comorbid conditions were
sought in hospital discharge and billing data from public and
private insurance programs and used to add specificity to case
classification, along with Current Procedural Terminology®
(CPT®) and National Drug Codes (NDC) for common medical
procedures and treatments found in outpatient and pharmacy
billing data.

Lessons Learned
Administrative data are collected for billing purposes, not
surveillance or research. Many individual records had several
ICD codes listed because the provider considered them as
possible diagnoses, even if those diagnoses later were ruled
out. Therefore, it was important to look for more than one
instance of a particular diagnosis when attempting to count
true cases of disease.

Resources Needed

Case comparison across datasets was limited due to the lack of
consistency in ICD coding for the hemoglobinopathy-related
complications, treatments, and procedures used in the RuSH
case definition. For example, while hospital discharge and
billing data provided evidence for complications via ICD codes,
only outpatient billing data supplied CPT® and NDC to identify
medical procedures and treatments.

Identification of hemoglobinopathy cases in Georgia was a
team effort, as much of the administrative data necessary
for the surveillance project were not within the purview of
Public Health. Thus, the project required partnerships and
data-sharing agreements between Public Health and the
state Medicaid/Children’s Health Insurance Program (CHIP)
agency, as well as the entity that collects, standardizes, and
manages the state’s hospital discharge data, the Georgia
Hospital Association (GHA), a nonprofit trade organization. It
was necessary for Public Health and the Georgia RuSH team

ICD codes were better at identifying SCD than thalassemia
because there were codes for subcategories of SCD, including
a code for sickle cell trait. There was only one category for
thalassemia in the ICD-9 classification and it did not distinguish
between thalassemia trait and thalassemia disease.

10

Registry and Surveillance System for Hemoglobinopathies

Sustainability/Translation

It was possible to create a surveillance system with
administrative data and it was determined that datasets with
better unique patient identifying information were more
favorable for matching and deduplication purposes. In the
absence of unique identifiers like social security numbers, many
assumptions needed to be made and deduplication took a
significant investment of time.

Additional funding is necessary to design and complete
validation studies that determine the accuracy of the RuSH
case definition. That is, what percentages of Level 2 and Level
3 cases actually have a hemoglobinopathy? Without additional
funding, it also will not be possible to define and identify
additional hemoglobinopathy cases outside of the study
period. One sustainable activity will be the use of administrative
data to advance the knowledge of health service use by
individuals with hemoglobinopathies.

Outcome
The Georgia RuSH team was able to use the individual-level
hospital discharge data to show the frequency of emergency
department (ED) visits and inpatient stays in each county, and
to characterize disease prevalence by age group, sex, race
and ethnicity, and county of residence. This information was
provided in poster form to sickle cell support groups around
the state for use in their outreach and advocacy efforts.
Findings reinforced community experience regarding areas of
the state with the greatest disease burden, the needs of youth
transitioning to adult care, and the nature of hospital spending
on hemoglobinopathy-related care. Better prevalence data
now can be shared with partners. For example, the percentage
of patients with SCD covered by Medicaid can be estimated.
Medicaid claims data also can be used to evaluate the frequency
and type of care that patients with hemoglobinopathies receive
to help target provider education efforts.

This project can help to inform surveillance activities for
other noninfectious, chronic conditions that affect individuals
throughout their lifetime. In Georgia, a first step would be
to approach the GHA and state Medicaid agency about
reporting all birth defects of children up to 8 years of age.
While birth defects currently are reportable in Georgia, the
system is passive and reporting compliance is low. Insurance
or provider organizations, or both, could provide a service for
their members by periodically searching their administrative
databases for specific ICD codes and reporting cases to the
Public Health Department.
Contact Information
Brendan Noggle, MPH
rbnoggle@dhr.state.ga.us
404-463-2099
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California:
Obtaining and Using Medicaid Data for
Hemoglobinopathy Surveillance
Program Overview

Resources Needed

California’s focus in the RuSH project has been to identify
as many cases as possible of sickle cell disease (SCD) and
thalassemia using administrative and clinical data. Using
the methodology and case definitions developed by the
seven funded states and the Centers for Disease Control and
Prevention, over 5,800 confirmed or probable cases of SCD
were identified in the state in 2008, which represents over 90%
of the estimated number of cases based on extrapolations of
case count from demographic data.1 Additionally, over 1,000
confirmed cases of alpha or beta thalassemia were identified in
2008, and algorithms are being developed to better determine
probable cases from the data.

California RuSH employed two full-time staff: a project
director/epidemiologist responsible for obtaining data from
agencies and clinics and a database developer who managed
and cleaned all datasets, developed matching algorithms
across them, and linked and deduplicated the cleaned data.
California’s Department of Health Care Services (DHCS) is the
agency responsible for the Medi-Cal program, and data were
requested directly from it for this project. The state’s Committee
for the Protection of Human Subjects declared the RuSH
project to be a nonresearch surveillance activity prior to the
contract being established with the DHCS; however, the DHCS
required a review and approval by its own Data and Research
Committee before granting access to data. This review was a
multistep process in which the RuSH project staff requested
particular variables, such as social security numbers, patient
ZIP Codes, and exact dates of birth from all claims related to
individuals who had one or more SCD- or thalassemia-related
ICD-9 codes during the period 2000–2008. The committee
approved, denied, or requested more information on the
justification for each variable. Approval took over 6 months,
while transfer of the initial data set took an additional 4 months
from approval to receipt.

Obtaining administrative and clinical data to do this work
was successful. Access was granted to (1) newborn screening
data going back as far as 1999; (2) all electronically available
hospital discharge and emergency room visit data and vital
records (birth and death certificates); and (3) data for patients
with SCD or thalassemia attending clinics at the Children’s
Hospital & Research Center Oakland and Children’s Hospital Los
Angeles (both have adult SCD and thalassemia clinics, as well
as pediatric clinics). In addition, Medi-Cal (California’s Medicaid
system) data related to members with one or more SCD- or
thalassemia-related International Classification of Disease,
(ICD-9) codes was made available.

Once the initial dataset was received from the DHCS, it was
compared to the datasets already received from other agencies
and clinic partners, and a list of cases seen in the other
sources—but not in the Medi-Cal data—was created. That
list was sent to the DHCS with a request to pull all claims seen
for those individuals as well; this request was granted quickly.
Once all data were received, weighted matching algorithms
were developed to enable linking and deduplication of data
using social security numbers. When linking had taken place,
work with the claims themselves was begun. Because this
data source had not been developed with an eye toward
research or surveillance (as in the case of hospital discharge

Medi-Cal data were the most difficult data to obtain and to
work with; however, while each of these sources was vital in
helping identify cases or contributing key information about
cases found, or both, Medi-Cal data contained the greatest
number of cases not seen elsewhere and the most information
about cases seen.
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Sustainability/Translation

data, for example), extensive data cleaning and translation
were necessary. Five different billing code systems were
used (e.g., International Classification of Disease, 9th Revision;
Current Procedural Terminology®; and Healthcare Common
Procedure Coding System) in one variable, and these needed
to be standardized. Some identified cases had two distinct
identification numbers: some claims were located by social
security number, while others were found using a countyspecific Medi-Cal identifier. Rather than receiving cleaned data,
the RuSH team received a data file that included all claim “lines”;
because of this, many of the encounters in the claims data were
entered multiple times to account for claim corrections and
resubmissions. These duplicate entries were accounted for in
analyses involving counts of visits or claims or dollar amounts.
Solving these problems was one of the most time-consuming
elements of the RuSH project.

California currently is seeking other funding sources to continue
surveillance of hemoglobinopathies and looking toward the
development of an ongoing patient registry. While there is no
funding in place to continue the collection of administrative
or clinical data, the CA RuSH team is optimistic that the utility
of the work done to understand the public health implications
of hemoglobin disorders among the state’s population will
lead to funding for continued work. In addition to establishing
a baseline count and understanding of the effects of SCD
and thalassemia among the population, this work has set the
stage for the use of administrative and clinical data to conduct
surveillance for other genetic disorders.
The use of Medicaid claims data in conjunction with other data
sources can be a powerful tool in public health surveillance,
allowing both effective case identification and an abundance
of information on complications, treatments, and outcomes for
the cases, including outpatient and prescription information
not readily available via other administrative data sources.
Obtaining and working with the data were not straightforward,
but the data’s utility more than made up for the difficulties in
gaining access to it.

Lessons Learned
States using Medicaid data for disease surveillance would be
advised to recognize the differences between that data source
and other administrative data sources. For example, hospital
discharge data produced at the state level can be a researchor surveillance-ready product, with variables cleaned and
well explained in a data dictionary. Budgeting extra time for
obtaining and working with the data is advised. Additionally,
should an “eligibility file” describing when members’ eligibility
for benefits began and ended be available, states are advised
to request that information. Such files allow the analysis of
Medicaid members as a cohort with appropriate censoring
dates.

References:
7. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The
number of people with sickle-cell disease in the United
States: national and state estimates. Am J Hematol. 2010
Jan;85(1):77–8. PubMed PMID: 20029951.
Contact Information
Lisa Feuchtbaum, DrPH, MPH
lisa.feuchtbaum@cdph.ca.gov
510-412-1455
www.casicklecell.org

Outcome
Despite challenges, Medi-Cal data were found to be well
worth the time and effort to the project. In the case of SCD, an
estimated 545 (14%) of 3,901 probable cases were identifiable
only through the Medi-Cal record, a much greater proportion
than from any other single data source, and 3,958 (64%) of
6,208 confirmed and probable SCD cases had data in the
Medi-Cal file. Similarly, among the 1,920 probable cases of
thalassemia, 287 (15%) were seen only in the Medi-Cal data,
and 6,194 (38%) of the 16,504 probable or possible cases were
seen in the Medi-Cal data. Additionally, all information about
outpatient services and prescription treatments for identified
cases came from this source.
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Pennsylvania:
The Use of Partnerships in Creating a
Hemoglobinopathy Database
Program Overview

had been treated in the past. CMU brought in the computer
resource and de-identification technologies, database
management, and data linkage expertise to the partnership.
Coordinating the process of creating the database required
frequent conference calls with the partners, and time and effort
dedicated to the project beyond that spent tracking patients
and completing usual duties.

The Pennsylvania Department of Health (PA DOH) developed
a linked data surveillance system for patients with sickle cell
disease (SCD) or thalassemia in Pennsylvania. Due to privacy
issues that could not be resolved within a reasonable time
frame, the PA DOH could not obtain data from vital statistics,
Medicaid, or the Pennsylvania Health Care Cost Containment
Council’s (PHC4) hospital discharge database. As a result, the
PA DOH established a partnership with the three leading
childrens hospitals in Pennsylvania: St. Christopher’s Hospital
for Children, The Children’s Hospital of Philadelphia® (CHOP),
and Children’s Hospital of Pittsburgh (CHIP) to aggregate
descriptive data about their respective populations with SCD
and thalassemia, as well as Carnegie Mellon University (CMU)
to provide analytical support for de-identifying, cleaning, and
linking the databases. The databases used to link the newborn
screening dataset to the vital statistics data were the hospital
administrative databases from the previously listed hospitals.
These databases were created to incorporate data specific to
patients with SCD or thalassemia. These datasets contained
the data elements that were decided on by the RuSH Data
and Harmonization workgroup. Fine-grained Record Linkage
software was used to link all of the databases used in this
project. The individuals on the RuSH team from each of the
three childrens hospitals negotiated with the information
technology department at their respective facilities to create
a dataset of patients with SCD or thalassemia who met the
criteria set up by the workgroup.

CMU’s Management Science & Healthcare Informatics
research group was instrumental in supporting the project
through its expertise in data privacy, cleaning, and linkage.
It was absolutely necessary to have the group’s expertise
to harmonize all of the data sources. Because all of the data
already existed within the three childrens hospitals and the PA
DOH, there were no costs incurred to obtain the data.

Lessons Learned:
Working with partners to establish timelines for data
submission can be a very challenging process, especially when
integrating numerous sources of data from different software
platforms and dealing with different institutional policies
and practices. Allowing for plenty of time and flexibility to
discuss and resolve any problems that arise in the process is
essential. Assembling the appropriate teams with expertise
in the clinical domains; epidemiology and public health;
information technology as applied to health care data and
resources; analytic capabilities and project management; and,
most importantly, knowledge of and links with the target
community of patients with SCD also is essential to the success
of such projects. One of Pennsylvania’s limitations regarding
this database was that data that were related to the adult
population who had SCD or thalassemia were not included.
Future collaborations will be able to obtain data related to
adults with these diseases.

Resources
Each institute brought its own unique qualities to this
partnership. The PA DOH provided the newborn screening
database to the partnership and the staff to assist in the
coordination of the development of the linked database. The
hospitals each brought a wealth of data about its patients
with SCD or thalassemia who currently were being treated or
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Outcomes

allocating funds). The data collection process also has led to the
increase of statewide understanding of the populations with
SCD or thalassemia and the associated service use data.

The formation of a partnership that was integral in
accomplishing the construction of a hemoglobin database
containing data from three separate treatment facilities and
PA DOH’s newborn screening database was a tremendous
accomplishment for the state. Participating in this process
provided a close to accurate account of the population
of people with SCD or thalassemia living in Pennsylvania,
especially the pediatric population, and the service use
of treatment centers and community-based organization
resources that are funded through contract agreements with
the state. A stronger foundation to assess resource needs for
the populations with SCD and thalassemia also was established.

In addition, the process has emphasized the need to store
newborn screening information and to maintain hospital
system disease-specific databases until more innovative
information technology systems are available. This also will help
guide or modify the information collected for quarterly state
reporting and answer questions such as: Are the appropriate
data being provided or do modifications need to be made?
Pennsylvania also is well positioned to conceptualize and
develop a statewide registry for SCD and thalassemia that can
build on the integrated solution developed for the current
effort. RuSH objectives that were accomplished from this data
linkage project included collaboration, by involving appropriate
within-state partners, and data integration, by linking
information from the three childrens hospitals, the PA DOH’s
newborn screening data, and the state’s vital records.

From the International Classification of Disease, Revision 9
codes included in the database from each hospital, the PA
RuSH team was able to translate these codes into the types of
hospital services that were used by the pediatric population
with SCD. This information then can be translated into actual
dollars that can be used in a cost analysis (i.e., actual cost of
average admission vs. insurance reimbursement; average cost
of fever admission vs. reimbursement).

Sustainability/Translation
While the PA RuSH team has been successful in obtaining data
from three hospitals catering to the needs of a large number of
children with hemoglobinopathies, gaps in surveillance remain.
Ongoing efforts to secure data user agreements between
the DOH, PHC4, and Department of Public Welfare (DPW)
will enable these data to be linked. Meetings with the DPW
concerning these issues currently are under way. Discussions
with the PHC4 will take place in the near future.

The PA DOH now has a more accurate snap shot of the
populations with SCD or thalassemia in Pennsylvania. There
also is a better understanding of the data linkage methods and
mechanisms needed to aggregate statewide data about service
use and resources needed for specific diagnosis groups. As a
result of the work of the partnership, it will be possible to create
a data hierarchy that can be used as a tool to determine what
information or data are most helpful in understanding specific
population needs.

The establishment of these partnerships hopefully will serve as
a model to expand the surveillance program to include other
hospitals in Pennsylvania, as well as information on the adult
population with SCD or thalassemia. Successful integration of
data from the PHC4 and the DPW would enhance greatly efforts
to accomplish this model surveillance program goal.

As grantees of the PA DOH Sickle Cell Service grant, the CHOP,
CHIP, and sickle cell hemoglobinopathy centers (SCHC) are
required to provide quarterly reports to demonstrate sickle
cell management and psychosocial service use. Through
participation in RuSH, it was recognized that the existing
reporting template could be modified to provide a more
comprehensive snapshot of the patient population with SCD,
and its service and resource use in the state of Pennsylvania.
More specifically, the process of compiling surveillance data
presented an opportunity for the PA DOH and its grantees to
revisit current quarterly reporting fields and assess whether
the right questions were being asked to determine service and
resource use and create a data hierarchy as a tool to address
specific circumstances (e.g., addressing populations needs or

Contact Information:
William Cramer, MEd
wcramer@pa.gov
717-783-8143
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Florida:
Creating a Physician Reporting Website
Program Overview

Lessons Learned

Members of the Florida RuSH team, designed a website that
allows physicians throughout the state to submit laboratory
confirmed sickle cell disease (SCD) and thalassemia patient
information, including personal identifiers such as name, social
security number, date of birth, home address, place of birth,
sex, race, and ethnicity for accurate linking of multiple source
datasets used in the RuSH project (hospital discharge data,
vital statistics, Children’s Medical Services, Memorial Healthcare
System, and Medicaid) and to aid in case confirmation. The
website is completely secure and entered data is accessible
only by Florida Department of Health staff. A physician creates
a profile and is assigned a site identification number. Physician
support staff can create a subaccount linked to the physician for
purposes of entering data on the physician’s behalf. To ensure
the accuracy of data input by staff, the physician logs into the
website to review and confirm data that then are transmitted to
Florida Department of Health staff.

The biggest hurdles we overcame in the creation and
implementation of a physician reporting website were
understanding the challenges of a physician’s busy practice
and identifying dedicated staff to enter data. Data were entered
when staff had an opportunity to do so. It was essential
to identify the person in the physician’s office who was
responsible for this task and work directly with him or her to
facilitate the process or suggest to the physician bringing in an
outside person for the project.

Outcome
The physician reporting website was launched in February
2012. Technical support was provided to sites and the first
data entry began in April 2012, with 120 inputs in the first 48
hours. A total of 159 cases have been reported since then.
The highest volume (53.21%) of cases was represented by
hemoglobin SS (HbSS) . There were 6 cases of thalassemia and
12 cases reported as “Other Variant” as the diagnosis, including
persistent fetal hemoglobin, Diamond Blackfan anemia, HbSN
Baltimore, and HbCC.

Clinicians with the highest volume of patients were identified
through the hospital databases and subsequently contacted by
our team, who encouraged them to enter SCD and thalassemia
patient data into the website. Physicians identified through
churches and social groups were also invited to enter data. In
addition, the Cooley’s Anemia Foundation was contacted, and
responded with a list of physicians in Florida who provide care
to individuals with thalassemia.

Sustainability/Translation
Results of specific physician-reported cases can be shared with
the reporting physician and aggregate data can be shared
with all physicians caring for this patient population to observe
the course of a disease, to understand variations in treatment
and outcomes, to examine factors that influence prognosis
and quality of life, and to describe care patterns, including
appropriateness of care and disparities in the delivery of care.

Resources Needed
The creation of a physician reporting website required the
support of an experienced Web designer. Discussions with
staff knowledgeable in health informatics, record linkage, and
epidemiology, as well as with physicians, also were needed
to define the types and formats of the data to be collected.
Using the recommendations provided during these discussions,
the website was designed and built. Furthermore, a list of
physicians who provided confirmatory testing for the state
newborn screening program and clinicians with high volumes
of patients with SCD or thalassemia was essential to target the
appropriate physicians to provide data. Financial incentives of
$25 per patient record entered were offered to each physician
to offset the time and effort required on their part.

It is unlikely that the Florida RuSH project activities will be
sustained without continued extra-mural funding. The budget
situation for state government in Florida continues to require
scaling back of vital programs and services, and very few new
programs have been funded in the past three years. While
we plan to utilize the results of the RuSH project for health
education activities and will continue to work with providers
as well as support groups, without funding for data acquisition,
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linkage and integration, and analysis, the surveillance portion of
RuSH will likely not continue unless a new funding mechanism
is obtained.

outreach seems well suited to tracking other conditions and could
be useful for other rare disorders and blood-related diseases.
Contact Information:
Mary Beth Vickers, RN, MSN
Marybeth_vickers@doh.state.fl.us
850-245-4222
www.cms-kids.com

Moving forward, the approach utilized by the Florida RuSH team
has potential to extend to a number of other genetic disorders
and health conditions that pose continual challenges to those
affected across their lifespan. Our model that included public
health, epidemiology and informatics, clinician leaders, and

Michigan:
Creating a Statewide Hemoglobinopathy
Long-Term Follow-Up Module
Program Overview

potentially unscreened infants. Cases are matched using birth
certificate identifiers and other unique information such as the
infant’s name, mother’s name, and infant’s date of birth. All
linked records are uploaded weekly into the MCIR and profiles
for children with abnormal hemoglobinopathy screening results
are created automatically in the MCIR hemoglobinopathy
module with newborn screening results determining the
default case diagnosis.

Since 1987, children identified with sickle cell disease (SCD)
through Michigan’s Newborn Screening Program have been
followed from birth through 5 years of age by the State
of Michigan. To provide more comprehensive follow-up
through the lifespan, Michigan recently developed a Webbased hemoglobinopathy follow-up module in the already
established Michigan Care Improvement Registry (MCIR).

Computer programmers with a background in the
immunization components of the MCIR were tasked with
the design and creation of a customized MCIR module for
hemoglobinopathies. Follow-up duties (e.g., tracking status
of penicillin prophylaxis and documenting home visits and
telephone calls) were integrated into the application based
on already established follow-up protocols in collaboration
with the Sickle Cell Disease Association of America, Michigan
Chapter (SCDAA-MI). In Michigan, the SCDAA-MI is responsible
for provision of comprehensive services to all newborns
with hemoglobinopathies detected by newborn screening.
Data fields were established and approved by Michigan’s
Hemoglobinopathy Quality Improvement Committee, an active
group of pediatric and adult hematologists practicing across
the state. Data fields include: newborn screening laboratory
results, confirmatory test results, penicillin prophylaxis start
dates, ongoing status of prophylaxis through age five, and
self-reported health status information, including demographic
variables and barriers to care.

The hemoglobinopathy MCIR application allows for improved
programmatic communication and invaluable information for
hemoglobinopathy surveillance. The primary objective was to
develop a Web-based follow-up module to monitor:
8. Diagnosis of all newborns referred with positive screening
results for SCD.
9. Initiation of penicillin prophylaxis.
10. Hemoglobinopathy education and social work services.
11. Self-reported complications, screenings, and treatments
related to SCD.

Resources Needed
Michigan birth records have been linked with newborn
screening records since 2007. This linkage is completed
weekly in the Division of Genomics, Perinatal Health, and
Chronic Disease Epidemiology at the Michigan Department
of Community Health using Link Plus software to identify
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Lessons Learned:

Sustainability/Translation:

Development and acceptability of a Web-based MCIR
hemoglobinopathy module was successful as a result of
significant time, staff, and funds expended specifically for this
project. Replication of the module might be challenging for
other institutions due to both the infrastructure and resources
that are required for implementation. Building a similar module
with fewer interactive and automated mechanisms still could
serve as an effective surveillance tool without full-scale
integration of every follow-up, communication, and reporting
activity. In Michigan, this Web-based registry proved extremely
useful for communication across different communities and
allowed for health results and concerns to be identified in real
time. This Web-based component also will be essential for
any future integration of this module in sickle cell clinics by
hematologists.

A transition will take place during the final 6 months of RuSH
funding, changing the title of this self-reported data collection
initiative to “Sickle Cell Voices”. Ongoing feedback will be used
for quality improvement measures as questions are revised and
adapted in the coming year. With enough momentum behind
the hemoglobinopathy MCIR module, further completion of
health status assessments and tracking of routine follow-up
through the MCIR will continue past the end of the RuSH
project. The Michigan Newborn Screening Program is in a
secure position to fund troubleshooting and technical support
to ensure that the application continues to be used to its fullest
capacity. Newborn screening staff will monitor data collection
for quality assurance, creating periodic briefs and reports.
Applications for future data analysis will endure as surveillance
information from the hemoglobinopathy MCIR module
continues to grow with time.

Outcome:

Contact Information:
William Young, PhD
517-335-8938

Regional patient advocates working for the SCDAA-MI have
been documenting all follow-up activities for their clients in
the hemoglobinopathy MCIR module since January 2011. Case
profiles also are being created continually for older clients
with SCD, with the goal of having baseline information for
all patients with SCD from birth through 25 years of age in
the MCIR by 2013. Data from the module will be included
in a comprehensive surveillance and data report on SCD
in Michigan, future educational campaigns, and potential
advocacy initiatives. Michigan will continue to validate the
data through a link between health status assessment findings
and Medicaid claims. The health status assessment findings
will provide valuable feedback to Michigan’s hematologists,
serve as the basis for adapting clinical protocols, and
stimulate future research and program initiatives in Michigan’s
hemoglobinopathy quality improvement committee.
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New York:
Case Ascertainment of Individuals With
Hemoglobinopathies Not Identified Through
Newborn Screening
Program Overview:

Resources Needed:

As a result of newborn screening (NBS), all babies born in
New York State (NYS) since 1975 have been screened for
hemoglobinopathies. However, individuals born before
screening began, in another country, in another state, or
outside of a hospital setting are not in the NBS database.
Therefore, such individuals must be sought out to provide
the most accurate count of people living in NYS with these
disorders, as well as available clinical information related to
those individuals.

The goal of this project was to identify clinical case patients
while minimizing the burden of data collection to center staff.
Labor shortage was a common hurdle to overcome at centers
when working on case identification and data extraction. To
assist with these concerns, RuSH project staff worked with
providers at each center to ensure an effective IRB submission.
In addition, RuSH project staff helped draft patient consent
forms, develop data entry tools needed for data collection,
and offered their own services to perform site visits to centers
to assist with review of patient records. As such, the resources
required to complete clinical data collection included a
substantial time commitment from and collaboration among
team members, travel expenses associated with site visits
to centers, and software to design and build a user-friendly
database with an intuitive form of interface for data entry of
patient information.

To identify such cases, letters were sent to providers at 31
pediatric hemoglobinopathy specialty care centers (HgbSCCs)
informing them about the RuSH project and asking for them
to participate in clinical data review of any patients seen and
treated at their centers during the period 2004–2009. Those
centers interested in participating in RuSH were sent copies
of the project protocol, the executive summary, a list of data
elements to be collected, and a copy of the NYS Department of
Health’s Institutional Review Board (IRB) approval of the project.
Due to Health Insurance Portability and Accountability Act
(HIPAA) privacy laws concerning individually identifiable health
information, all RuSH project tasks concerning collection of
personally identifiable information were subject to review and
approval by each institution’s IRB. Follow-up was conducted
with each of the providers by telephone or email, or both,
over the next several months to guide interested providers
in submitting protocols to each of their IRBs prior to moving
forward with data review.

Lessons Learned:
Outreach to providers and corresponding clinical data
collection required a substantial time commitment, constant
communication, and organization. Regular communication
with providers and center staff throughout the IRB submission
process and the subsequent data collection efforts were
essential to ensure timely progress. It was essential to have all
key documents (project protocol, letters, approvals, etc.) on file
and accessible to external partners working with RuSH team
members, as these documents provided the backbone of IRB
submissions at individual centers. IRB approval of the RuSH
project varied considerably among institutions. Therefore, it
was also essential to be flexible and available when working
with providers to assist them in preparing the materials needed
for their IRB submissions, to assist in drafting documents as
requested, and to provide answers to questions posed by IRB
panelists.

In addition, a letter from the NY State Commissioner of Health
was sought to give the RuSH principal investigators the
authority to collect data on patients with hemoglobinopathy
for the purpose of establishing a patient registry. As a result, an
order was issued under Public Health Law 206 (1)(j) in January
2012 doing so. Both documents were distributed with the aim
of facilitating IRB approval at individual HgbSCCs.
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Sustainability/Translation:

It sometimes took months for an individual center to move
through the steps from the initial decision to participate in
RuSH, to an effective IRB submission, to performing case
identification of patients. This preceded the actual data
collection itself, which might have involved a site visit for record
review and data extraction. It was important to allot enough
time for this process. For future projects involving clinical data,
it is recommended that—in addition to structuring the research
design in compliance with privacy and HIPAA laws–a legislative
mandate or letters from the proper authority granting access
to clinical data be obtained. Also, additional labor and funding
would be useful for the work involved in chart review and data
extraction.

Now that the groundwork has been laid and contacts have
been established with providers in treatment centers around
NYS, and particularly in the New York City area, continued
communication and collaboration might continue past the
end of the RuSH project period. The next step following this
work will be to reach out to adult HgbSCCs. In previous RuSH
community outreach projects, the NY RuSH team administered
surveys to providers at adult HgbSCCs to assess the longterm health care status of patients, determine what clinical
information was collected by the centers, and explore the
possibility of data collection and sharing of patient data with
the RuSH project team. Based on the responses received,
available clinical data from patients seen at these centers will be
sought, following the same protocol established for outreach
to pediatric centers. In future data collection efforts, funding
would be an essential component to success, as staffing is
necessary for the work involved in data review and data entry
of hundreds of cases. Hospitals have limited resources to
allocate to these tasks without funding for necessary staff.

Outcome:
A summary of our outreach efforts follows: 31 pediatric centers
were contacted initially regarding RuSH clinical data collection;
7 centers received IRB approval and have begun the case
identification and data collection process; 9 other centers have
shown interest in participation, but are at various stages in the
IRB discussion and approval process; seven centers opted out
of participation due to resource issues, such as time and labor;
and no response was received from 8 centers after repeated
attempts at contact. At each of the approved centers, the
New York RuSH team was able to identify cases not previously
identified through NBS. The clinical data, representing several
hundred cases, should shed some light on the prevalence
of hemoglobinopathies and the most common treatments
administered to patients. The current list of IRB approved
centers comprises: New York-Presbyterian/Weill Cornell Medical
Center, New York Methodist Hospital, Brookdale University
Hospital and Medical Center, Staten Island University Hospital,
Interfaith Medical Center, Women & Children’s Hospital of
Buffalo, and Bronx-Lebanon Hospital Center.

Contact Information:
Ying Wang, PhD, MPH
wxy01@health.state.ny.us
518-402-7716
www.wadsworth.org/newborn/RuSH/rush_overview.html
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Notes:
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